Statement Of Investor Complaints For The Quarter Ended June 2018
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0660 Name of the Signatory :- M AdinarayanaDesignation :- Company Secretary and Compliance Officer Natco Pharma launches Hepatitis C drug
Natco Pharma has launched a fixed dose combination of Sofosbuvir-Daclatasvir tablets for the treatment of Hepatitis C under the brand name Hepcinat Announcement under Regulation 30 (LODR)-Press Release / Media Release
NATCO launches fixed dose combination of Sofosbuvir-Daclatasvir drug for Hepatitis C treatment in INDIA Announcement under Regulation 30 (LODR)-Press Release / Media Release
NATCO launches generic Posaconazole Injection- 1st time available in INDIA Announcement under Regulation 30 (LODR)-Investor Presentation
Corporate presentation for the FY 2017-18. Natco Pharma profit leaps 70%
Natco Pharma has posted a profit of 299.7 core for the fourth quarter ended March 31, 2018, against a profit of 176.4 crore, up 69.9 per cent for th Audited Financial Results For The Year Ended 31St March 2018
Audited Financial Results for the year ended 31st March 2018 Board Meeting-Outcome of Board Meeting
Financial Results for the Quarter and Year ended 31st May, 2018 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
The Company will host an Earnings Call with Investors / Analysts at 11.00 a.m. IST on May 24, 2018 to disseminate Financial Results of the company for the quarter and year ended 31st March, 2018